Tim Kutzkey Buys 2,562 Shares of Surrozen (NASDAQ:SRZN) Stock

Surrozen, Inc. (NASDAQ:SRZN) Director Tim Kutzkey acquired 2,562 shares of the company’s stock in a transaction that occurred on Friday, January 16th. The stock was bought at an average cost of $20.00 per share, with a total value of $51,240.00. Following the purchase, the director owned 1,007,090 shares in the company, valued at $20,141,800. The trade was a 0.26% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink.

Tim Kutzkey also recently made the following trade(s):

• On Tuesday, January 20th, Tim Kutzkey purchased 18,052 shares of Surrozen stock. The shares were bought at an average price of $19.60 per share, with a total value of $353,819.20.
• On Thursday, January 15th, Tim Kutzkey purchased 11,893 shares of Surrozen stock. The stock was acquired at an average price of $19.89 per share, with a total value of $236,551.77.
• On Wednesday, January 14th, Tim Kutzkey bought 5,523 shares of Surrozen stock. The stock was bought at an average price of $19.99 per share, for a total transaction of $110,404.77.
• On Tuesday, January 13th, Tim Kutzkey bought 12,470 shares of Surrozen stock. The shares were purchased at an average cost of $19.80 per share, with a total value of $246,906.00.
• On Tuesday, January 6th, Tim Kutzkey bought 15,100 shares of Surrozen stock. The shares were acquired at an average cost of $19.89 per share, with a total value of $300,339.00.
• On Friday, December 5th, Tim Kutzkey bought 30,884 shares of Surrozen stock. The shares were bought at an average price of $19.54 per share, for a total transaction of $603,473.36.
• On Thursday, December 4th, Tim Kutzkey acquired 5,266 shares of Surrozen stock. The shares were bought at an average cost of $17.35 per share, for a total transaction of $91,365.10.
• On Thursday, November 13th, Tim Kutzkey purchased 315,457 shares of Surrozen stock. The stock was acquired at an average cost of $12.65 per share, with a total value of $3,990,531.05.

Surrozen Stock Performance

Shares of SRZN opened at $19.17 on Thursday. The firm has a market capitalization of $164.29 million, a P/E ratio of -0.86 and a beta of 0.58. Surrozen, Inc. has a 52 week low of $5.90 and a 52 week high of $24.94. The stock has a 50 day moving average price of $19.11 and a two-hundred day moving average price of $14.17.

Surrozen (NASDAQ:SRZN) last released its earnings results on Friday, November 7th. The company reported ($3.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($2.44). Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. The business had revenue of $0.98 million during the quarter. On average, equities analysts forecast that Surrozen, Inc. will post -8.49 earnings per share for the current year.

Key Stories Impacting Surrozen

Here are the key news stories impacting Surrozen this week:

• Positive Sentiment: Director Tim Kutzkey completed several open‑market buys on Jan 6, 13, 14, 15, 16 and 20 totaling tens of thousands of shares (~$641k reported across the most recent three purchases) and now directly owns ~1.02M shares — insider accumulation is often read as a bullish confidence vote. Surrozen (NASDAQ:SRZN) Director Purchases $51,240.00 in Stock
• Positive Sentiment: Major shareholder Group GP LP Column III mirrored the insider purchases (Jan 15, 16 and 20), increasing its stake by ~1.2–1.8% per disclosed tranche to ~1.02M shares — coordinated buying by a large holder reinforces the positive insider signal. Surrozen (NASDAQ:SRZN) Major Shareholder Group Gp Lp Column III Acquires 2,562 Shares
• Neutral Sentiment: The disclosures are routine SEC beneficial‑ownership filings that document the trades and updated holdings; they do not indicate corporate actions (e.g., buybacks or financings) by Surrozen itself. SEC filing — Kutzkey purchases
• Negative Sentiment: Company fundamentals remain weak: Surrozen reported a steep Q3 EPS miss (reported -$3.61 vs -$1.17 expected) and minimal revenue, leaving substantial operating losses that could cap the stock’s upside unless clinical or commercial progress materially improves. MarketBeat — SRZN profile

Hedge Funds Weigh In On Surrozen

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Citadel Advisors LLC lifted its holdings in Surrozen by 32.8% in the third quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock valued at $179,000 after acquiring an additional 3,424 shares during the period. Geode Capital Management LLC raised its holdings in Surrozen by 22.6% in the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock worth $277,000 after purchasing an additional 5,702 shares during the period. Acuta Capital Partners LLC raised its stake in shares of Surrozen by 5.0% during the 3rd quarter. Acuta Capital Partners LLC now owns 178,415 shares of the company’s stock worth $2,299,000 after buying an additional 8,415 shares during the period. Stonepine Capital Management LLC grew its stake in Surrozen by 7.1% in the 2nd quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock valued at $2,736,000 after acquiring an additional 20,247 shares during the period. Finally, Vanguard Group Inc. increased its stake in shares of Surrozen by 21.7% during the third quarter. Vanguard Group Inc. now owns 266,418 shares of the company’s stock worth $3,433,000 after purchasing an additional 47,468 shares in the last quarter. Institutional investors own 66.57% of the company’s stock.

Wall Street Analysts Forecast Growth

SRZN has been the subject of a number of recent analyst reports. Lifesci Capital raised Surrozen to a “strong-buy” rating in a research report on Thursday, November 13th. Wall Street Zen raised Surrozen to a “sell” rating in a report on Friday, November 28th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Surrozen in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $32.00.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.